FDA approves Hikma’s generic version of Novo’s diabetes drug Victoza
The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the treatment in the country. Hikma’s branded generic will compete with Teva Pharmaceuticals authorized generic of Victoza in the United States that was launched earlier this year. Authorized … Read more